Six billion oseltamivirs, two competing items.

Nearly 6 billion oseltamivir markets, two competing products reportedrecently, Chengdu Cente 3 generic drug "phosphate oseltamivir dry suspension" listed application by the Drug Review Center (CDE) to undertake - to this end, Chengdu Perteootamive dry suspension agent, phosphate oseltamivir capsule double-productit is understood that on April 2, Chengdu Cente also submitted an application for the listing of class 4 generic drugs of oseltamivir phosphate capsulesat present, there are many pharmaceutical companies in the country reported the production of oseltamivir new dosage forms, including dry-mixed suspension agentThe data show that compared with the capsule, the dry-mixed suspension agent has obvious clinical value and advantage smaller for the special population with swallowing difficulty, compared with the granules, it has unique advantages in the aspect of masking and taste, and the compliance of children patients is betteras a result,, Shenzhen Bemey Pharmaceuticals signed a licensing and cooperation agreement with Hetero of India in June 2019 to declare the dry-mix suspension as a child-specific dosage formIn August and December 2019, Alvogen and Hetero of the United States submitted an application for the listing of new imported drugs in China in accordance with category 5.2 (applications for of offshore generic drugs on the domestic market), which will eventually be listed on the use of "children's medicine" or will be preferred for reviewon the current progress of the declaration, Xintai Pharmaceutical's phosphate oseltamivir cosuspender in March 21, 2020 daily listing, the current review status for the queue for review, Shenzhen Bemei Pharmaceuticals also for the queue for review, Xintai Pharmaceutical son for the first domesticis best known for its capsule-based dosage forms compared to the innovative dosage type of dry-mixed suspensionDomestic approved production of oseltamivir dosage forms for capsules (originally developed Roche, Dongsun, Shanghai Pharmaceuticals), granulated agent (East Sunshine)The agent forms are available in capsules, granules, dry-mixed suspensions and oral disintegrating tabletsmeters net data show that in China's urban public hospital terminals, Oselavir 2019 dosage pattern is 65% of dispersants and granules, 34.95% of capsulesfor the oseltamia capsule this dosage form, Seiber blue in the mine net data query, in addition to supplementary applications, there are already Xintai Pharmaceuticals and Chengdu Pett's Oselavir capsules on December 5, 2019 and April 2, 2020 declared on the marketpublic information shows that oseltamivir is a special drug for influenza, influenza diagnosis and treatment program (2019 edition) announced China's current market anti-flu virus drugs, mainly neuraminidase inhibitors, hemagglutinin inhibitors and M2 ion channel blockers threeAmong them, neuraminidase inhibitors are effective against influenza A and B, including oseltamivir (capsules/particles), zanamivir (inhalation spray), paramivirOstaway's original research manufacturer is Roche, the commodity name Dafi, around 2006, Roche will be Oselay wand has been authorized to Shanghai Chinese and Western Pharmaceuticals, East Sunshine Pharmaceutical selling, with the product name "Alfie" and "Kwei" listed for sale but The Production of Oseltamivir in Shanghai's Chinese and Western Medicine industry is not in circulation, so the domestic Oseltamivir market East Sunshine Medicine is a single big, as early as 2017 took the domestic market share of 90%, has now been the first through the consistency evaluation meter net data also clearly shows this point: in the Oseltaway TOP20 brand pattern, although a total of three pharmaceutical companies occupy the market, but the East Sunshine Pharmaceuticals is a crushing trend, the market share of 93.26%, Roche 6.2%, and Shanghai China-West 3D pharmaceutical industry is only 0.54% 's 2019 annual report shows that turnover was RMB6.224 billion, up 147.9% YoY, and shareholders' profit stake was RMB1,919 million, up 103.6% YoY insight database shows that the East Sunshine medicine in the raw materials also dominate: at present, only Yichang East Sunshine Yangtze River Pharmaceuticals, Shanghai West West 3and and Roche have production approval, but the Three-dimensional and Roche have expired, only the East Sunshine's number in use From the raw material supply, Dongsun medicine still has the advantage of home-grown after the baptism of the national collection, the industry agreed that the integration of raw materialpreparation enterprises will have more advantages in the market competition While maintaining some advantages of API, enterprises can expand to the downstream preparation field, by virtue of cost advantage by domestic collection of dongfeng to seize the preparation market, performance mainly rely on new production capacity, new product introduction and preparation winning bid and other factors driven therefore, Dongsun has its own raw materials, will have an advantage in price competition, the future Of Xintai and Chengdu Pertecancan can grab how much of the market, but also wait and see 6 billion, not the ceiling of Oselbeve February 24, Dongsun Pharmaceuticals issued a profit forecast, is expected to 2019 equity shareholders should account for profit will increase by more than 120% year-on-year, thanks to the company's core products, Weiwei (Oselbev) sales revenue continued to grow, product penetration in the country's medical institutions continue to improve, the company is also continuing to strengthen in the professional academic promotion of products Cypress Blue's database query in the Minenet, from 2015 to 2019, even though it is already more than 100 million varieties, Oselbev still maintains an annual market growth rate of more than 50%, and continues to rise Growth rates for 2015 to 2019 were 54.25%, 70.64%, 75.58% and 111.88%, respectively from the above data, even though Oselbev has reached 2.6 billion in 2018 at the city's public hospital terminals, it will continue to double to 111 percent in 2019 , the same, oseltamivir is likely to continue to grow at a high rate in 2020, and that the domestic Oselbevico coother is still a blank market with more room for exploration , such as dry suspension agent, has advantages in the treatment of infant sinpatients, in 6 mg /ml, 12 mg /ml specifications, can be flexible to meet the dose requirements of different weight pediatric patients Xintai Pharmaceuticals, Dongsun and Chengdu Pertei Pharmaceuticals also saw this market and carried out bioequivalence tests of oseltamicoin phosphate future in the Oseltamivir this big variety, there is still a large market space waiting for enterprises to dig Where is the upper limit of the market, the emergence of competition will be the East Sunshine Drug's 6 billion market impact, can wait for the market to give us answers.